AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms
of idiopathic Parkinson’s Disease (PD) as initial monotherapy and as adjunct therapy
to levodopa.
IMPORTANT SAFETY INFORMATION ABOUT AZILECT
Azilect is contraindicated with meperidine; the analgesics tramadol, methadone,
and propoxyphene; the antitussive agent dextromethorphan; as well as St. John’s
wort and cyclobenzaprine. Azilect is also contraindicated with other MAOIs.
In general, the combination of Azilect and antidepressants should be avoided. Caution
should be used when giving Azilect concurrently with CYP1A2 inhibitors such as ciprofloxacin.
Patients with moderate to severe hepatic impairment should not take Azilect. The
daily dose of Azilect should not exceed 1 mg because of the risks associated with
nonselective inhibition of MAO. PD patients are advised to monitor for melanoma
frequently and see a dermatologist on a regular basis.
The most common side effects as monotherapy include: flu syndrome, arthralgia, depression,
and dyspepsia; and as adjunct to levodopa therapy include: dyskinesia, accidental
injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal
pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.
AZL101023762/101241